Medtide Inc. (HKG:3880)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
22.60
+0.32 (1.44%)
At close: Mar 6, 2026
Market Cap3.20B
Revenue (ttm)546.29M +34.3%
Net Income121.20M +46.6%
EPS0.97 +75.4%
Shares Out141.80M
PE Ratio23.31
Forward PE13.94
Dividendn/a
Ex-Dividend Daten/a
Volume68,900
Average Volume120,349
Open22.10
Previous Close22.28
Day's Range21.90 - 22.60
52-Week Range21.50 - 41.72
Betan/a
RSI37.73
Earnings DateMay 29, 2026

About Medtide

Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, preclinical research, clinical development, and commercial-stage production services. It offers peptide new chemical entity discovery synthesis, peptide chemistry, manufacturing, and control development and commercial manufacturing services. The company focuses on developing oral and/or injectable glucagon, such as peptide-1 (GLP-1) molecule products. Its research and development technology platform include OmniPeptSynth, PeptiConjuX, Pept... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 520
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3880
Full Company Profile

Financial Performance

In 2024, Medtide's revenue was 442.23 million, an increase of 31.31% compared to the previous year's 336.77 million. Earnings were 59.17 million, an increase of 21.00%.

Financial numbers in CNY Financial Statements